JDRF RESEARCH IMPACT

JDRF is the leading global organization focused on type 1 diabetes (T1D) research. With the generous help of our supporters, JDRF is pursuing a diversified, dynamic research agenda aimed at moving us ever closer to a world without T1D.

RESEARCH PLAN

JDRF research focuses on therapies that are key to moving us toward a world without T1D:

- **Artificial Pancreas**: systems that can automatically deliver more effective and precise insulin and multi-hormone therapy
- **Complications**: therapies that prevent or better treat T1D-related damage such as eye and kidney disease
- **Encapsulation**: cell replacement therapies in a protective device that can provide long-term relief from insulin therapy without the need for intensive immune suppression
- **Glucose Control**: treatments that will improve the body’s glycemic balance through innovative and personalized therapies beyond the use of insulin alone
- **Smart Insulin**: novel insulins that can turn on and off in response to changing blood-glucose levels
- **Restoration**: restoring the body’s ability to produce insulin, which would represent a biological cure for T1D
- **Prevention**: therapies that will keep individuals, especially those at higher risk, from ever developing T1D

RESEARCH FUNDING

- **$6M** Multi-category Programs
- **$16M** Artificial Pancreas
- **$98M** RESEARCH FUNDING
- **$31M** Restoration
- **$14M** Prevention
- **$5M** Glucose Control (including Smart Insulin)
- **$13M** Complications
- **$13M** Encapsulation
- **$31M** Restoration
- **$14M** Prevention
- **$5M** Glucose Control (including Smart Insulin)
- **$13M** Complications
- **$13M** Encapsulation

RESEARCH FACTS AND FIGURES

JDRF ranked as top non-governmental diabetes research funder: an independent analysis of key diabetes-related scientific literature ranked JDRF as the third most frequent funder of diabetes research globally behind only the U.S. National Institutes of Health and National Science Foundation of China.

- **$1.9B** CUMULATIVE RESEARCH FUNDING SINCE 1970
- **$150M** SPECIAL DIABETES PROGRAM FEDERAL FUNDING
- **45** HUMAN CLINICAL TRIALS OF POTENTIAL T1D THERAPIES
- **17** COUNTRIES AROUND THE GLOBE

JDRF.org

Updated in March 2015
T1D TODAY

Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone people need to get energy from food. T1D strikes both children and adults and has nothing to do with diet or lifestyle. There is currently nothing you can do to prevent it. People with T1D must regularly monitor their blood sugar level, inject or continually infuse insulin through a pump, and carefully balance their insulin doses with eating and daily activities throughout the day and night. However, insulin is not a cure for diabetes, and even with intensive disease management, a significant portion of the day is still spent with either high or low blood sugar levels, placing people with T1D at risk for devastating complications such as heart attack, stroke, blindness, and amputation.

T1D FACTS AND FIGURES

21% INCREASE IN NUMBER OF U.S. YOUTH WITH T1D BETWEEN 2001 AND 2009

5M PEOPLE ARE EXPECTED TO HAVE T1D

THIS INCLUDES A 3-FOLD GROWTH IN YOUTH WITH T1D TO NEARLY 600,000

16% HISPANIC
9% BLACK
3% OTHER
72% WHITE

1.25M AMERICANS HAVE TYPE 1 DIABETES

29M AMERICANS HAVE SOME FORM OF DIABETES

ABOUT 5% OF AMERICANS WITH DIABETES HAVE T1D

Less than one-third of people with T1D in the U.S. are achieving target blood glucose control levels

TID is associated with an estimated loss of life expectancy of up to 13 years

84% OF THE PEOPLE WITH T1D ARE ADULTS

40,000 PEOPLE ESTIMATED TO BE DIAGNOSED WITH T1D EACH YEAR IN THE U.S.

$14B T1D-ASSOCIATED U.S. HEALTHCARE COST

Updated in March 2015

JDRF.org